RU2597790C2 - Способ обработки частиц активных фармацевтических ингредиентов - Google Patents
Способ обработки частиц активных фармацевтических ингредиентов Download PDFInfo
- Publication number
- RU2597790C2 RU2597790C2 RU2012149459/15A RU2012149459A RU2597790C2 RU 2597790 C2 RU2597790 C2 RU 2597790C2 RU 2012149459/15 A RU2012149459/15 A RU 2012149459/15A RU 2012149459 A RU2012149459 A RU 2012149459A RU 2597790 C2 RU2597790 C2 RU 2597790C2
- Authority
- RU
- Russia
- Prior art keywords
- active pharmaceutical
- ingredient
- active
- pharmaceutical ingredient
- cavitation
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 63
- 239000008186 active pharmaceutical agent Substances 0.000 title claims abstract description 45
- 239000002245 particle Substances 0.000 title claims abstract description 45
- 238000009826 distribution Methods 0.000 claims abstract description 14
- 239000002904 solvent Substances 0.000 claims abstract description 13
- 210000004072 lung Anatomy 0.000 claims abstract description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 239000000725 suspension Substances 0.000 claims description 35
- 239000000843 powder Substances 0.000 claims description 17
- 238000001694 spray drying Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 10
- 229960004123 mometasone furoate monohydrate Drugs 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 6
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 5
- 229960000289 fluticasone propionate Drugs 0.000 claims description 5
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 5
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims description 4
- 229960001469 fluticasone furoate Drugs 0.000 claims description 4
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229960000257 tiotropium bromide Drugs 0.000 claims description 4
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 3
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 3
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 3
- 229960002848 formoterol Drugs 0.000 claims description 3
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 3
- 229960001888 ipratropium Drugs 0.000 claims description 3
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims description 3
- 229960002052 salbutamol Drugs 0.000 claims description 3
- 229960004017 salmeterol Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229960000195 terbutaline Drugs 0.000 claims description 3
- 229950000210 beclometasone dipropionate Drugs 0.000 claims description 2
- 229940092705 beclomethasone Drugs 0.000 claims description 2
- 229960002537 betamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 2
- 229960004648 betamethasone acetate Drugs 0.000 claims description 2
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 229960002714 fluticasone Drugs 0.000 claims description 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 229960001067 hydrocortisone acetate Drugs 0.000 claims description 2
- 229960001664 mometasone Drugs 0.000 claims description 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 2
- 229960002744 mometasone furoate Drugs 0.000 claims description 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical group O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims description 2
- 229960005018 salmeterol xinafoate Drugs 0.000 claims description 2
- 229940110309 tiotropium Drugs 0.000 claims description 2
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 2
- 229960004436 budesonide Drugs 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- MQLXPRBEAHBZTK-SEINRUQRSA-M tiotropium bromide hydrate Chemical compound O.[Br-].C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 MQLXPRBEAHBZTK-SEINRUQRSA-M 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 22
- 238000010951 particle size reduction Methods 0.000 description 13
- 230000008569 process Effects 0.000 description 11
- 239000007921 spray Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000000227 grinding Methods 0.000 description 6
- 239000011521 glass Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000634 powder X-ray diffraction Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- -1 mometasone furoate Chemical class 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000001238 wet grinding Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000004497 NIR spectroscopy Methods 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- GVLGAFRNYJVHBC-UHFFFAOYSA-N hydrate;hydrobromide Chemical compound O.Br GVLGAFRNYJVHBC-UHFFFAOYSA-N 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- CBHOWTTXCQAOID-UHFFFAOYSA-L sodium ethane formaldehyde mercury(2+) molecular iodine 2-sulfidobenzoate Chemical compound [Na+].[Hg++].C[CH2-].II.C=O.[O-]C(=O)c1ccccc1[S-] CBHOWTTXCQAOID-UHFFFAOYSA-L 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT105058 | 2010-04-21 | ||
| PT105058A PT105058B (pt) | 2010-04-21 | 2010-04-21 | Processo para processamento de partículas de ingredientes activos farmacêuticos |
| PCT/GB2011/000631 WO2011131947A2 (en) | 2010-04-21 | 2011-04-21 | A process for particle processing of active pharmaceutical ingredients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012149459A RU2012149459A (ru) | 2014-05-27 |
| RU2597790C2 true RU2597790C2 (ru) | 2016-09-20 |
Family
ID=44194836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012149459/15A RU2597790C2 (ru) | 2010-04-21 | 2011-04-21 | Способ обработки частиц активных фармацевтических ингредиентов |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9956144B2 (enExample) |
| EP (1) | EP2560620B1 (enExample) |
| JP (2) | JP6347608B2 (enExample) |
| CN (1) | CN102970978B (enExample) |
| BR (1) | BR112012026941A2 (enExample) |
| CA (1) | CA2796978C (enExample) |
| IL (1) | IL222596B (enExample) |
| MX (1) | MX338594B (enExample) |
| PL (1) | PL2560620T3 (enExample) |
| PT (1) | PT105058B (enExample) |
| RU (1) | RU2597790C2 (enExample) |
| SG (1) | SG185003A1 (enExample) |
| WO (1) | WO2011131947A2 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8691145B2 (en) | 2009-11-16 | 2014-04-08 | Flodesign Sonics, Inc. | Ultrasound and acoustophoresis for water purification |
| EP3689364A1 (en) | 2010-02-08 | 2020-08-05 | Shenzhen Evergreen Therapeutics Co., Ltd. | Methods for the use of progestogen as a glucocorticoid sensitizer |
| US10987361B2 (en) | 2010-02-08 | 2021-04-27 | Shenzhen Evergreen Therapeutics Co., Ltd. | Treating auto-immune and auto-inflammatory diseases |
| US10993879B2 (en) | 2010-02-08 | 2021-05-04 | Shenzhen Evergreen Therapeutics Co., Ltd. | Pulmonary delivery of progestogen |
| US9421553B2 (en) | 2010-08-23 | 2016-08-23 | Flodesign Sonics, Inc. | High-volume fast separation of multi-phase components in fluid suspensions |
| US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9783775B2 (en) | 2012-03-15 | 2017-10-10 | Flodesign Sonics, Inc. | Bioreactor using acoustic standing waves |
| US10370635B2 (en) | 2012-03-15 | 2019-08-06 | Flodesign Sonics, Inc. | Acoustic separation of T cells |
| US9688958B2 (en) | 2012-03-15 | 2017-06-27 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US9796956B2 (en) | 2013-11-06 | 2017-10-24 | Flodesign Sonics, Inc. | Multi-stage acoustophoresis device |
| US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9567559B2 (en) | 2012-03-15 | 2017-02-14 | Flodesign Sonics, Inc. | Bioreactor using acoustic standing waves |
| US9752114B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc | Bioreactor using acoustic standing waves |
| US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US9272234B2 (en) | 2012-03-15 | 2016-03-01 | Flodesign Sonics, Inc. | Separation of multi-component fluid through ultrasonic acoustophoresis |
| PT106237B (pt) * | 2012-03-30 | 2015-03-19 | Hovione Farmaci Ncia S A | Produção de partículas substancialmente monodispersas utilizando moagem e separação por membranas |
| US11324873B2 (en) | 2012-04-20 | 2022-05-10 | Flodesign Sonics, Inc. | Acoustic blood separation processes and devices |
| US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
| PT106738B (pt) * | 2013-01-09 | 2015-06-08 | Hovione Farmaciencia Sa | Método para o controlo do fenómeno de degradação difusional de ostwald (ostwald ripening) no processamento de partículas de um ingrediente farmacêutico |
| SG11201508804QA (en) * | 2013-04-25 | 2015-11-27 | Flodesign Sonics Inc | Excipient removal from pharmacological samples |
| US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
| EP3738592B1 (en) | 2013-10-08 | 2022-01-26 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| PT107433B (pt) * | 2014-01-28 | 2018-12-04 | Hovione Farm S A | Processo de redução e controlo do tamanho de partícula |
| MX2016010373A (es) | 2014-02-11 | 2016-11-30 | Lam Therapeutics Inc | Rapamicina para el tratamiento de linfangioleiomiomatosis. |
| US10307371B2 (en) | 2014-02-11 | 2019-06-04 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| PT107567B (pt) * | 2014-03-31 | 2019-02-13 | Hovione Farm S A | Secador por atomização com atomizador múltiplo, método para o aumento de escala de pós para inalação secos por dispositivo de atomização múltiplo e uso de vários atomizadores num secador por atomização |
| BR112016022598A8 (pt) | 2014-04-04 | 2021-06-29 | Ai Therapeutics Inc | composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso |
| US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
| RU2732908C2 (ru) | 2014-10-07 | 2020-09-24 | ЭйАй ТЕРАПЬЮТИКС, ИНК. | Ингаляционная лекарственная форма рапамицина для лечения легочной гипертензии |
| MA40910A (fr) | 2014-11-07 | 2017-09-12 | Civitas Therapeutics Inc | Poudres de rapamycine pour administration pulmonaire |
| WO2016130645A1 (en) | 2015-02-10 | 2016-08-18 | Lam Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| US10106770B2 (en) | 2015-03-24 | 2018-10-23 | Flodesign Sonics, Inc. | Methods and apparatus for particle aggregation using acoustic standing waves |
| PT108368B (pt) | 2015-03-31 | 2018-11-05 | Hovione Farm S A | Produção contínua de partículas |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| CA2984492A1 (en) | 2015-04-29 | 2016-11-03 | Flodesign Sonics, Inc. | Acoustophoretic device for angled wave particle deflection |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| EP3297740A1 (en) | 2015-05-20 | 2018-03-28 | Flodesign Sonics Inc. | Acoustic manipulation of particles in standing wave fields |
| US10161926B2 (en) | 2015-06-11 | 2018-12-25 | Flodesign Sonics, Inc. | Acoustic methods for separation of cells and pathogens |
| WO2016205334A1 (en) | 2015-06-16 | 2016-12-22 | Vascular Strategies Llc | Drug delivery and imaging chemical conjugate, formulations and methods of use thereof |
| CA2995043C (en) | 2015-07-09 | 2023-11-21 | Bart Lipkens | Non-planar and non-symmetrical piezoelectric crystals and reflectors |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| PT109030B (pt) | 2015-12-15 | 2019-09-25 | Hovione Farmaciência, S.A. | Preparação de partículas inaláveis de zafirlucaste |
| US10710006B2 (en) | 2016-04-25 | 2020-07-14 | Flodesign Sonics, Inc. | Piezoelectric transducer for generation of an acoustic standing wave |
| EP3481361A1 (en) | 2016-05-03 | 2019-05-15 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| JP2020513248A (ja) | 2016-10-19 | 2020-05-14 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響による親和性細胞抽出 |
| KR20220066413A (ko) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| IL309073A (en) | 2021-06-03 | 2024-02-01 | Arcadia Medicine Inc | Enantiomeric entactogen compounds and methods of their use. |
| JP2025522774A (ja) | 2022-07-04 | 2025-07-17 | ホビオネ サイエンティア リミテッド | 吸入用被覆結晶形態乾燥粉末の乾燥粉末吸入器用医薬組成物 |
| WO2025064867A1 (en) * | 2023-09-21 | 2025-03-27 | Yuva Biosciences, Inc. | Delivery system for mitochondrial health enhancers |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6187765B1 (en) * | 1997-10-09 | 2001-02-13 | Schering Corporation | Mometasone furoate suspensions for nebulization |
| EP1834624A1 (en) * | 2005-01-07 | 2007-09-19 | Eisai R&D Management Co., Ltd. | Medicinal composition and process for producing the same |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19875032I2 (de) | 1990-09-10 | 2007-04-19 | Schering Corp | Mometason-Furoate-Monohydrat, Verfahren zu seiner Herstellung und das enthaltende pharmazeutische Zusammensetzungen |
| US6184765B1 (en) * | 1999-01-07 | 2001-02-06 | Nec Research Institute, Inc. | Switch useful at superconducting temperatures and comprising superconducting material |
| US6555139B2 (en) * | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
| GB9925934D0 (en) * | 1999-11-03 | 1999-12-29 | Glaxo Group Ltd | Novel apparatus and process |
| GB0125604D0 (en) * | 2001-10-25 | 2001-12-19 | Glaxo Group Ltd | Novel process |
| JP4684545B2 (ja) | 2002-09-26 | 2011-05-18 | 大日本住友製薬株式会社 | 溶出性の良好なイソキサゾール誘導体経口製剤 |
| ES2566486T3 (es) | 2004-03-31 | 2016-04-13 | Toyama Chemical Co., Ltd. | Dispersión fina de fármaco moderadamente soluble y proceso de producción de la misma |
| EP1595534A1 (en) * | 2004-05-13 | 2005-11-16 | Universiteit Utrecht Holding B.V. | Gel composition comprising charged polymers |
| EP1828100A1 (en) * | 2004-12-17 | 2007-09-05 | Cipla Ltd. | Pharmaceutical compounds and compositions |
| US20060193818A1 (en) * | 2005-02-25 | 2006-08-31 | Southall Michael D | Compositions containing amines and use thereof |
| DE102005011786A1 (de) | 2005-03-11 | 2006-09-14 | Pharmasol Gmbh | Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen |
| GB0523576D0 (en) | 2005-11-18 | 2005-12-28 | Theradeas Ltd | Drug composition and its use in therapy |
| US20070178051A1 (en) | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
| EP2170279B1 (en) * | 2007-07-31 | 2017-12-27 | Otsuka Pharmaceutical Co., Ltd. | Methods for producing aripiprazole suspension and freeze-dried formulation |
| EP2050437A1 (en) | 2007-10-15 | 2009-04-22 | Laboratoires SMB | Improved pharmaceutical dry powder compositions for inhalation. |
| EP2156823A1 (en) * | 2008-08-14 | 2010-02-24 | Pharmatex Italia Srl | Process for the preparation of sterile powdered pharmeceutical compounds in the form of micro and nanoparticles |
-
2010
- 2010-04-21 PT PT105058A patent/PT105058B/pt active IP Right Grant
-
2011
- 2011-04-21 WO PCT/GB2011/000631 patent/WO2011131947A2/en not_active Ceased
- 2011-04-21 CA CA2796978A patent/CA2796978C/en active Active
- 2011-04-21 PL PL11718765T patent/PL2560620T3/pl unknown
- 2011-04-21 US US13/642,397 patent/US9956144B2/en active Active
- 2011-04-21 CN CN201180024407.2A patent/CN102970978B/zh active Active
- 2011-04-21 EP EP11718765.8A patent/EP2560620B1/en active Active
- 2011-04-21 BR BR112012026941A patent/BR112012026941A2/pt not_active Application Discontinuation
- 2011-04-21 JP JP2013505534A patent/JP6347608B2/ja active Active
- 2011-04-21 SG SG2012078614A patent/SG185003A1/en unknown
- 2011-04-21 MX MX2012012215A patent/MX338594B/es active IP Right Grant
- 2011-04-21 RU RU2012149459/15A patent/RU2597790C2/ru active
-
2012
- 2012-10-21 IL IL222596A patent/IL222596B/en active IP Right Grant
-
2016
- 2016-09-09 JP JP2016176303A patent/JP6857467B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6187765B1 (en) * | 1997-10-09 | 2001-02-13 | Schering Corporation | Mometasone furoate suspensions for nebulization |
| EP1834624A1 (en) * | 2005-01-07 | 2007-09-19 | Eisai R&D Management Co., Ltd. | Medicinal composition and process for producing the same |
Non-Patent Citations (1)
| Title |
|---|
| GABRIELLE PILCER et al. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery. International Journal of Pharmaceutics 365 (2009), p. 162-;169 CHAN L. W. et al. Process Analytical Technology: Application to Particle Sizing in Spray Drying. AAPS PharmSciTech, Vol. 9, No. 1, March 2008, p. 259-266 * |
Also Published As
| Publication number | Publication date |
|---|---|
| PL2560620T3 (pl) | 2021-04-06 |
| IL222596B (en) | 2019-03-31 |
| CN102970978B (zh) | 2017-05-10 |
| PT105058A (pt) | 2011-10-21 |
| WO2011131947A3 (en) | 2012-01-05 |
| MX2012012215A (es) | 2013-05-09 |
| JP6857467B2 (ja) | 2021-04-14 |
| CN102970978A (zh) | 2013-03-13 |
| JP2017019845A (ja) | 2017-01-26 |
| JP6347608B2 (ja) | 2018-06-27 |
| CA2796978C (en) | 2019-07-02 |
| SG185003A1 (en) | 2012-11-29 |
| JP2013525338A (ja) | 2013-06-20 |
| US20130203717A1 (en) | 2013-08-08 |
| US9956144B2 (en) | 2018-05-01 |
| EP2560620A2 (en) | 2013-02-27 |
| EP2560620B1 (en) | 2020-09-16 |
| IL222596A0 (en) | 2012-12-31 |
| CA2796978A1 (en) | 2011-10-27 |
| RU2012149459A (ru) | 2014-05-27 |
| PT105058B (pt) | 2013-04-17 |
| MX338594B (es) | 2016-04-25 |
| BR112012026941A2 (pt) | 2016-07-12 |
| WO2011131947A2 (en) | 2011-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2597790C2 (ru) | Способ обработки частиц активных фармацевтических ингредиентов | |
| JP6499187B2 (ja) | 支援された粒子径低減方法 | |
| Vandana et al. | An overview on in situ micronization technique–An emerging novel concept in advanced drug delivery | |
| KR100799432B1 (ko) | 신규 조성물 | |
| JP2013525338A5 (enExample) | ||
| CA2510263C (en) | Preparation of sterile aqueous suspensions comprising micronised crystalline active ingredients for inhalation | |
| KR101834940B1 (ko) | 나노입자 제조방법 | |
| DK153920B (da) | Toert, pulverformigt allergenmateriale og fremgangsmaade til fremstilling deraf | |
| CN108463213B (zh) | 可吸入扎鲁司特颗粒的制备 | |
| JP2011506400A (ja) | 有機化合物 | |
| Xi et al. | Inhalable aerosol microparticles with low carrier dosage and high fine particle fraction prepared by spray-freeze-drying | |
| Carr et al. | Particle formation of budesonide from alcohol-modified subcritical water solutions | |
| KR20200014902A (ko) | 비정질 나노구조 제약 물질 | |
| ES2831019T3 (es) | Un procedimiento para el procesamiento de partículas de ingredientes farmacéuticos activos | |
| CN112823798A (zh) | 牛蒡子苷与牛蒡子苷元在制备治疗和/或预防皮肤炎症的药物中的应用 | |
| CN104523805A (zh) | 冠心苏合分散片及其制备方法 |